BridgeBio Pharma, Inc.
BBIOHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeBridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The $13.40B market capitalization puts BBIO squarely in large-cap range for its industry. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Market Cap
$13.40B
Beta
0.97
P/E (TTM)
—
P/E (Fwd)
-305.23
EPS (TTM)
$-3.56
EPS (Fwd)
$-0.22
ROE
—
ROA
-26.0%
Cash
$720.2M
Total Debt
$3.37B
Free CF
-$320.3M
52W Change
7.9%
Annual Financials
Cash vs Debt
Where BBIO stands vs its 150-day and 200-day moving averages
As of the October 6, 2026 close, BBIO finished 9.68% below its 150-day moving average ($73.23) and 10.05% below its 200-day moving average ($73.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BBIO overbought or oversold?
At the October 6, 2026 close, BBIO's RSI(14) was 41.8, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $720.2M in cash, though total debt stands at $3.37B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$320.3M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has grown from $77.6M (2022) to $502.1M (2025), reflecting a 547% increase over the period.
The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for BridgeBio Pharma, Inc. and its sector.